

PATIENT INFORMATION

Patient's Name:		SSN:		DOB:	
Address:		City:		State:	Zip:
Home Phone:	Cell:	Height:	Weight:	Gender: M F	
Email			Diagnosis Code:		

INSURANCE INFORMATION (or attach copy of the cards)

Primary Insurance:	Policy Holder:	Relationship:	Policy #:	Group #:
Secondary Insurance:	Policy Holder:	Relationship:	Policy #:	Group #:

PRESCRIPTION INFORMATION (for IV medication attach a copy of the prescription)

CIMZIA® (certolizumab pego) Prefilled Syringe Lyophilized Powder
 Induction: 400 mg (2 x 200 mg) SubQ weeks 0, 2, 4
Qty: 28 day supply **Refills:** 0
Maintenance:
 2 x 200 mg SubQ every 4 wks
 2 x 200 mg SubQ every 2 wks
 200 mg SubQ every 2 wks
Qty: 28 day supply **Refills:**

Entocort® (budesonide) 3 mg capsules
 9 mg PO daily
Qty: 90 **Refills:**

ENTYVIO® (vedolizumab)
 Induction: 300 mg intravenously weeks 0, 2, 6
Qty: 1 **Refills:** 2
 Maintenance: 300 mg intravenously every 8 weeks
Qty: 1 **Refills:**

HUMIRA® (adalimumab)
 Pen Prefilled Syringe
 Citrate Free (CF) Original Formula
Induction:
 160 mg SubQ day 1, 80 mg SubQ day 15
 80 mg SubQ day 1, 80 mg SubQ day 2/ 80 mg SubQ day 15
Qty: 1 pack **Refills:** 0
 Maintenance:
40 mg SubQ every other week
Qty: 28 day supply **Refills:**
**** If dosage form is not selected, PENS will be dispensed.****

INFLECTRA® (infliximab)
 Induction: 100 mg vials intravenously weeks 0, 2, 6
 Maintenance: 100 mg vials intravenously every 8 weeks
Qty: 28 day supply **Refills:**

REMICADE® (infliximab-dyyb) 5 mg/kg 10 mg/kg
 Induction: 100 mg vials intravenously weeks 0, 2, 6 **Qty:** 1
Refills: 0
 Maintenance: 100 mg vials intravenously every 8 weeks
Qty: 28 day supply **Refills:**

RINVOQ® (upadacitinib) extended-release tablets
 15 mg 30 mg 45 mg
 Induction: 45 mg PO once daily for 8 weeks
Qty: 2 bottles **Refills:** 0
 Maintenance: _____ mg once daily
Qty: **Refills:**

SIMPONI® (golimumab) Prefilled Syringe Autoinjector
 Induction: 200 mg (2 x 100 mg) SubQ at week 0
Qty: 2 syringes **Refills:** 0
 Maintenance: Starting at week 2 of treatment, 100 mg SubQ every 4 weeks
Qty: 28 day supply **Refills:**

STELARA® (ustekinumab)
 IV Induction: 260 mg (pt weight: ≤ 55 kg) 390 mg (pt weight: 56-85 kg)
 520 mg (pt weight: >85 kg)
Qty: **Refills:** 0
 Maintenance: Starting 8 weeks after IV induction dose, 90 mg SubQ every 8 weeks
Qty: 1

SOLESTA® (dextranomer and sodium hyaluronate) 1 ml Prefilled Syringe
 4 submucosal injections
Qty: 4 **Refills:**

UCERIS® (budesonide) 9 mg Extended-Release Tablet
 9 mg PO daily
Qty: 30 **Refills:**

XELJANZ® (tofacitinib)
 Induction: 10 mg PO twice daily for 8-16 week
Qty: **Refills:**
 Maintenance: 5 mg PO twice daily
Qty: 60 **Refills:**

XIFAXAN® (rifaximin) 200 mg tablet 550 mg tablet
 550 mg PO three times per day for 14 days
 200 mg PO three times per day for 16 days
 _____ mg PO _____ times per day for _____ days
Qty: **Refills:**

ZEPOSIA® (ozanimod)
 7-day titration: days 1-4: Give 0.23 mg PO once daily. days 5 to 7: Give 0.46 mg PO daily
Qty: 1 **Refills:** None
 Maintenance Dosing: Starting day 8, 0.92 mg PO once daily
Qty: 30 **Refills:**

OTHER:

STRENGTH:

SIG/DIRECTIONS:

QUANTITY:

REFILLS:

As required by your state, Prescriber to check "Dispense as written" or handwritten "Brand Medically Necessary" and Dispense as written sign to prevent generic substitution.

PHYSICIAN INFORMATION

Injection Training: Office to Instruct SP to Arrange Teaching

Prescriber Name:	Phone:	Fax:
Office Contact:	Email:	
Address:	Ship To:	<input type="checkbox"/> Patient <input type="checkbox"/> MD Office
NPI #:	Tax ID#:	
Prescription Signature:	Date:	